Analyst consensus rating
Bicycle Therapeutics Analyst Rating: Buy
BCYC is rated Buy by 6 analysts with a $9.50 target. As of 2026-08-24.
Direct answer
Bicycle Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.50.
Forecast evidence checked August 24, 2026.
Get free Bicycle Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.38
- Average price target
- $9.50
- High price target
- $14.00
- Low price target
- $5.00
- Low target gap
- +14.2%
- Target upside
- +116.9%
- High target gap
- +219.6%
- Target range width
- 205.5%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bicycle Therapeutics?
Bicycle Therapeutics has a verified Buy consensus. The same dataset has an average price target of $9.50.
How far are Bicycle Therapeutics's low and high targets from the recorded price?
The low target implies +14.2%, while the high target implies +219.6%.
How many analysts are included in Bicycle Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Bicycle Therapeutics's target upside or downside calculated?
The average target of $9.50 is divided by the recorded price of $4.38, then one is subtracted to produce +116.9%. This does not guarantee a future return.
When was Bicycle Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.